Milea Timbergen

330 References 1 . Al-Jazrawe M. Chapter 4: Clonal Expansion and CD142 Distinguish Interacting Neoplastic and Stromal Cells in Desmoid Tumors. Investigating the maintenance of desmoid tumors beyond beta-catenin. [Thesis]. In press 2019. 2 . De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer. 2008;123(10):2229-2238. 3 . Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432(7015):332-337. 4 . Smits R, van der Houven van Oordt W, Luz A, Zurcher C, Jagmohan-Changur S, Breukel C, et al. Apc1638N: a mouse model for familial adenomatous polyposis-associated desmoid tumors and cutaneous cysts. Gastroenterology. 1998;114(2):275-283. 5 . Naert T, Van Nieuwenhuysen T, Vleminckx K. TALENs and CRISPR/Cas9 fuel genetically engineered clinically relevant Xenopus tropicalis tumor models. Genesis. 2017;55(1-2):e23005. 6 . Alman B. Clonal Expansion and CD142 Distinguish Interacting Neoplastic and Stromal Cells in Desmoid Tumors: Desmoid Tumor Research Foundation; Available from: https://dtrf.org/desmoid-mouse-models/. 7 . Fletcher CDM, Bridge JA, PCWH, F M. World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of soft tissue and bone. Press: Lyon: IARC; 2013 2013. 8 . Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, et al. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007;29(1):19-24. 9 . Mercier KA, Walsh DM. The initiation, design, and establishment of the Desmoid Tumor Research Foundation Patient Registry and Natural History Study. Rare Tumors. 2019;11:2036361319880978. 10 . Basse C, Italiano A, Penel N, Mir O, Chemin C, Toulmonde M, et al. Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years. Int J Cancer. 2019;145(8):2135-2143. 11 . Penel N, Coindre JM, Bonvalot S, Italiano A, Neuville A, Le Cesne A, et al. Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. Eur J Cancer. 2016;58:90-96. 12 . Walker EA, Fenton ME, Salesky JS, Murphey MD. Magnetic resonance imaging of benign soft tissue neoplasms in adults. Radiol Clin North Am. 2011;49(6):1197-1217, vi. 13 . Braschi-Amirfarzan M, Keraliya AR, Krajewski KM, Tirumani SH, Shinagare AB, Hornick JL, et al. Role of Imaging in Management of Desmoid-type Fibromatosis: A Primer for Radiologists. Radiographics. 2016;36(3):767-782. 14 . Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205-216. 15 . Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. 16 . Planz VB, Lubner MG, Pickhardt PJ. Volumetric analysis at abdominal CT: oncologic and non-oncologic applications. Br J Radiol. 2019;92(1095):20180631. 17 . Bonvalot S, Ternes N, Fiore M, Bitsakou G, Colombo C, Honore C, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20(13):4096-4102. 18 . Colombo C, Miceli R, Le Pechoux C, Palassini E, Honore C, Stacchiotti S, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. European Journal of Cancer. 2015:186-192. 19 . Gounder MM, Mahoney MR, Van Tine BA, Ravi V, Attia S, Deshpande HA, et al. Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med. 2018;379(25):2417-2428. 12